Posttranscriptional regulation of surfactant protein-A messenger RNA in human fetal lung in vitro by glucocorticoids

Vijayakumar Boggaram, Margaret E. Smith, Carole R. Mendelson

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Surfactant protein-A (SP-A), the major pulmonary surfactant-associated protein, is a developmentally and hormonally regulated sialoglycoprotein of about 35,000 mol wt. In previous studies we observed that dexamethasone has dose-dependent biphasic effects on the levels of SP-A and its mRNA in human fetal lung in vitro. At concentrations of 10-10-10-9 M, dexamethasone increased the levels of SP-A and its mRNA over those of control tissues, whereas at concentrations ≥ 10-8 M, the steroid was markedly inhibitory. Our findings suggest that the inhibitory action of dexamethasone (>10-8 M) on SP-A mRNA levels was mediated by an effect to reduce SP-A mRNA stability, since the steroid caused a dose-dependent increase in the rate of transcription; however, an effect to increase transcription with premature termination leading to instability of mRNA transcripts could not be ruled out. In the present investigation we have studied in detail the mechanisms underlying the biphasic effects of glucocorticoids on SP-A mRNA levels in human fetal lung tissues in vitro. Our findings indicate that dexamethasone (10-7 M) has no adverse effect on the elongation of nascent mRNA transcripts throughout the SP-A gene; elongation of SP-A mRNA transcripts in dexamethasone-treated tissue expiants was similar to that observed in tissues incubated in control medium or medium containing (Bu)2CAMP. Therefore, premature termination of SP-A mRNA transcription leading to the instability of SP-A mRNA can be ruled out. On the other hand, we found that dexamethasone (10-7 M) had a pronounced effect to reduce the apparent half-life of SP-A mRNA; in control explants maintained in the presence of actinomycin-D to block gene transcription, the SP-A mRNA half-life was estimated to be 11.4 h, whereas in tissues also treated with dexamethasone, the SP-A mRNA half-life was reduced by more than 60% to 5.0 h. Dexamethasone also was found to have dose-dependent effects on the degradation of SP-A mRNA. After 12 h of incubation in the presence of actinomycin-D and dexamethasone at 10-9 and 10-7 M, the levels of SP-A mRNA were reduced by 50% and 80%, respectively, compared to those in tissue incubated with actinomycin-D alone. The inhibitory effects of glucocorticoids on SP-A mRNA levels were completely reversible and were blocked by the glucocorticoid antagonist RU486. Based on these findings, we suggest that the biphasic effects of glucocorticoids on SP-A mRNA levels in human fetal lung in vitro are caused by the differential actions of glucocorticoids on SP-A mRNA transcription and stability.

Original languageEnglish (US)
Pages (from-to)414-423
Number of pages10
JournalMolecular Endocrinology
Volume5
Issue number3
StatePublished - Mar 1991

Fingerprint

Pulmonary Surfactant-Associated Protein A
Glucocorticoids
Lung
Messenger RNA
Dexamethasone
RNA Stability
Dactinomycin
Half-Life
In Vitro Techniques
Pulmonary Surfactant-Associated Proteins
Steroids
Sialoglycoproteins

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology, Diabetes and Metabolism

Cite this

Posttranscriptional regulation of surfactant protein-A messenger RNA in human fetal lung in vitro by glucocorticoids. / Boggaram, Vijayakumar; Smith, Margaret E.; Mendelson, Carole R.

In: Molecular Endocrinology, Vol. 5, No. 3, 03.1991, p. 414-423.

Research output: Contribution to journalArticle

@article{3f398929ee654a138c3efc3426b26a68,
title = "Posttranscriptional regulation of surfactant protein-A messenger RNA in human fetal lung in vitro by glucocorticoids",
abstract = "Surfactant protein-A (SP-A), the major pulmonary surfactant-associated protein, is a developmentally and hormonally regulated sialoglycoprotein of about 35,000 mol wt. In previous studies we observed that dexamethasone has dose-dependent biphasic effects on the levels of SP-A and its mRNA in human fetal lung in vitro. At concentrations of 10-10-10-9 M, dexamethasone increased the levels of SP-A and its mRNA over those of control tissues, whereas at concentrations ≥ 10-8 M, the steroid was markedly inhibitory. Our findings suggest that the inhibitory action of dexamethasone (>10-8 M) on SP-A mRNA levels was mediated by an effect to reduce SP-A mRNA stability, since the steroid caused a dose-dependent increase in the rate of transcription; however, an effect to increase transcription with premature termination leading to instability of mRNA transcripts could not be ruled out. In the present investigation we have studied in detail the mechanisms underlying the biphasic effects of glucocorticoids on SP-A mRNA levels in human fetal lung tissues in vitro. Our findings indicate that dexamethasone (10-7 M) has no adverse effect on the elongation of nascent mRNA transcripts throughout the SP-A gene; elongation of SP-A mRNA transcripts in dexamethasone-treated tissue expiants was similar to that observed in tissues incubated in control medium or medium containing (Bu)2CAMP. Therefore, premature termination of SP-A mRNA transcription leading to the instability of SP-A mRNA can be ruled out. On the other hand, we found that dexamethasone (10-7 M) had a pronounced effect to reduce the apparent half-life of SP-A mRNA; in control explants maintained in the presence of actinomycin-D to block gene transcription, the SP-A mRNA half-life was estimated to be 11.4 h, whereas in tissues also treated with dexamethasone, the SP-A mRNA half-life was reduced by more than 60{\%} to 5.0 h. Dexamethasone also was found to have dose-dependent effects on the degradation of SP-A mRNA. After 12 h of incubation in the presence of actinomycin-D and dexamethasone at 10-9 and 10-7 M, the levels of SP-A mRNA were reduced by 50{\%} and 80{\%}, respectively, compared to those in tissue incubated with actinomycin-D alone. The inhibitory effects of glucocorticoids on SP-A mRNA levels were completely reversible and were blocked by the glucocorticoid antagonist RU486. Based on these findings, we suggest that the biphasic effects of glucocorticoids on SP-A mRNA levels in human fetal lung in vitro are caused by the differential actions of glucocorticoids on SP-A mRNA transcription and stability.",
author = "Vijayakumar Boggaram and Smith, {Margaret E.} and Mendelson, {Carole R.}",
year = "1991",
month = "3",
language = "English (US)",
volume = "5",
pages = "414--423",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Posttranscriptional regulation of surfactant protein-A messenger RNA in human fetal lung in vitro by glucocorticoids

AU - Boggaram, Vijayakumar

AU - Smith, Margaret E.

AU - Mendelson, Carole R.

PY - 1991/3

Y1 - 1991/3

N2 - Surfactant protein-A (SP-A), the major pulmonary surfactant-associated protein, is a developmentally and hormonally regulated sialoglycoprotein of about 35,000 mol wt. In previous studies we observed that dexamethasone has dose-dependent biphasic effects on the levels of SP-A and its mRNA in human fetal lung in vitro. At concentrations of 10-10-10-9 M, dexamethasone increased the levels of SP-A and its mRNA over those of control tissues, whereas at concentrations ≥ 10-8 M, the steroid was markedly inhibitory. Our findings suggest that the inhibitory action of dexamethasone (>10-8 M) on SP-A mRNA levels was mediated by an effect to reduce SP-A mRNA stability, since the steroid caused a dose-dependent increase in the rate of transcription; however, an effect to increase transcription with premature termination leading to instability of mRNA transcripts could not be ruled out. In the present investigation we have studied in detail the mechanisms underlying the biphasic effects of glucocorticoids on SP-A mRNA levels in human fetal lung tissues in vitro. Our findings indicate that dexamethasone (10-7 M) has no adverse effect on the elongation of nascent mRNA transcripts throughout the SP-A gene; elongation of SP-A mRNA transcripts in dexamethasone-treated tissue expiants was similar to that observed in tissues incubated in control medium or medium containing (Bu)2CAMP. Therefore, premature termination of SP-A mRNA transcription leading to the instability of SP-A mRNA can be ruled out. On the other hand, we found that dexamethasone (10-7 M) had a pronounced effect to reduce the apparent half-life of SP-A mRNA; in control explants maintained in the presence of actinomycin-D to block gene transcription, the SP-A mRNA half-life was estimated to be 11.4 h, whereas in tissues also treated with dexamethasone, the SP-A mRNA half-life was reduced by more than 60% to 5.0 h. Dexamethasone also was found to have dose-dependent effects on the degradation of SP-A mRNA. After 12 h of incubation in the presence of actinomycin-D and dexamethasone at 10-9 and 10-7 M, the levels of SP-A mRNA were reduced by 50% and 80%, respectively, compared to those in tissue incubated with actinomycin-D alone. The inhibitory effects of glucocorticoids on SP-A mRNA levels were completely reversible and were blocked by the glucocorticoid antagonist RU486. Based on these findings, we suggest that the biphasic effects of glucocorticoids on SP-A mRNA levels in human fetal lung in vitro are caused by the differential actions of glucocorticoids on SP-A mRNA transcription and stability.

AB - Surfactant protein-A (SP-A), the major pulmonary surfactant-associated protein, is a developmentally and hormonally regulated sialoglycoprotein of about 35,000 mol wt. In previous studies we observed that dexamethasone has dose-dependent biphasic effects on the levels of SP-A and its mRNA in human fetal lung in vitro. At concentrations of 10-10-10-9 M, dexamethasone increased the levels of SP-A and its mRNA over those of control tissues, whereas at concentrations ≥ 10-8 M, the steroid was markedly inhibitory. Our findings suggest that the inhibitory action of dexamethasone (>10-8 M) on SP-A mRNA levels was mediated by an effect to reduce SP-A mRNA stability, since the steroid caused a dose-dependent increase in the rate of transcription; however, an effect to increase transcription with premature termination leading to instability of mRNA transcripts could not be ruled out. In the present investigation we have studied in detail the mechanisms underlying the biphasic effects of glucocorticoids on SP-A mRNA levels in human fetal lung tissues in vitro. Our findings indicate that dexamethasone (10-7 M) has no adverse effect on the elongation of nascent mRNA transcripts throughout the SP-A gene; elongation of SP-A mRNA transcripts in dexamethasone-treated tissue expiants was similar to that observed in tissues incubated in control medium or medium containing (Bu)2CAMP. Therefore, premature termination of SP-A mRNA transcription leading to the instability of SP-A mRNA can be ruled out. On the other hand, we found that dexamethasone (10-7 M) had a pronounced effect to reduce the apparent half-life of SP-A mRNA; in control explants maintained in the presence of actinomycin-D to block gene transcription, the SP-A mRNA half-life was estimated to be 11.4 h, whereas in tissues also treated with dexamethasone, the SP-A mRNA half-life was reduced by more than 60% to 5.0 h. Dexamethasone also was found to have dose-dependent effects on the degradation of SP-A mRNA. After 12 h of incubation in the presence of actinomycin-D and dexamethasone at 10-9 and 10-7 M, the levels of SP-A mRNA were reduced by 50% and 80%, respectively, compared to those in tissue incubated with actinomycin-D alone. The inhibitory effects of glucocorticoids on SP-A mRNA levels were completely reversible and were blocked by the glucocorticoid antagonist RU486. Based on these findings, we suggest that the biphasic effects of glucocorticoids on SP-A mRNA levels in human fetal lung in vitro are caused by the differential actions of glucocorticoids on SP-A mRNA transcription and stability.

UR - http://www.scopus.com/inward/record.url?scp=0025759336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025759336&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 414

EP - 423

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 3

ER -